Lawmakers in New York this month approved wide-ranging legislation designed to require pricing transparency from PBMs and to eliminate key PBM practices, including so-called “spread pricing,” mid-year formulary shuffling and drug substitutions. But the bill could potentially limit plans’ ability to respond to pricing moves by manufacturers, one consultant says.
- Datapoint, Medicare and Medicaid
- Abstract, Drug Benefits
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits